Exchange: NASDAQ Sector: Healthcare Industry: Medical Devices
2.81% $9.14
America/New_York / 26 apr 2024 @ 16:00
FUNDAMENTALS | |
---|---|
MarketCap: | 16.63 mill |
EPS: | -34.12 |
P/E: | -0.270 |
Earnings Date: | May 09, 2024 |
SharesOutstanding: | 1.819 mill |
Avg Daily Volume: | 0.0091 mill |
RATING 2024-04-26 |
---|
B |
Neutral |
RATINGS | ||
---|---|---|
Rating CashFlow: | Neutral | |
Return On Equity: | Strong Sell | |
Return On Asset: | Sell | |
DE: | Buy | |
P/E: | Sell | |
Price To Book: | Buy |
QUARTER GROWTHS | ||||||
---|---|---|---|---|---|---|
3/22 | 4/22 | 1/23 | 2/23 | 3/23 | 4/23 | |
Revenue | ||||||
Gr.Profit | ||||||
Ebit | ||||||
Asset | ||||||
Debt |
PE RATIO: COMPANY / SECTOR |
---|
0.00x |
Company: PE -0.270 | sector: PE -3.05 |
PE RATIO: COMPANY / INDUSTRY |
---|
0.00x |
Company: PE -0.270 | industry: PE 222.16 |
DISCOUNTED CASH FLOW VALUE |
---|
N/A |
N/A |
Expected Trading Range (DAY) |
---|
$ 8.73 - 9.55 ( +/- 4.47%) |
ATR Model: 14 days |
Date | Person | Action | Amount | type |
---|---|---|---|---|
2023-08-01 | Lukowiak Andrew A | Buy | 30 575 | Stock option (right to buy) |
2023-08-01 | Lukowiak Andrew A | Buy | 0 | |
2023-07-17 | Markovich Rebecca | Buy | 13 071 | Stock option (right to buy) |
2023-06-09 | Baker Bros. Advisors Lp | Buy | 23 685 | Non- Qualified Stock Option (right to buy) |
2023-06-09 | Scott Randal W. | Buy | 95 000 | Stock option (right to buy) |
INSIDER POWER |
---|
80.48 |
Last 91 transactions |
Buy: 54 998 856 | Sell: 42 065 023 |
Indicator Signals | |
---|---|
RSI 21 | |
SMA | |
Trend | |
Trend 2 | |
Trend 3 | |
MACD |
Volume Signals | |
---|---|
Price | $9.14 (2.81% ) |
Volume | 0.0044 mill |
Avg. Vol. | 0.0091 mill |
% of Avg. Vol | 48.91 % |
Signal 1: | |
Signal 2: |
0 Signals | Accuracy: 0.00% | Accuracy Buy: 0.00% | Accuracy Sell: 0.00%
Avg return buy: 0.00 % | Avg return sell: 0.00 %
$1 invested is now $1.00 or 0.00% since Coming Soon
Date | Signal | @ | Closed | % |
---|
Talis Biomedical Corporation operates as a molecular diagnostic company. The company is developing the Talis One system to address limitations of existing point-of-care diagnostic testing technologies for infectious diseases. It also offers Talis One COVID-19 Test System, which focuses on detection of SARS-CoV-2, the virus that causes COVID-19. In addition, it develops Talis One assay kit for respiratory infections, infections related to women's health, and sexually transmitted infections; and other tests for the detection of other respiratory infections, such as a respiratory panel test to detect influenza A, influenza B, and respiratory syncytial virus. Talis Biomedical Corporation was incorporated in 2013 and is headquartered in Menlo Park, California.